MIAMI -- The Generic Pharmaceutical Association (GPhA) is creating a new division designed to deal exclusively with biosimilars with a separate board of directors, the association's leaders announced at the group's annual conference in Miami this week, and sources say the trade group is courting brand biologic giant Amgen to join, but Amgen says it is “satisfied with the balanced policies promoted by our existing trade associations.” Craig Wheeler, GPhA board of directors chair and president of Momenta Pharmaceuticals, said...